WARF: P03405US

  • Assigned to WARF as biological material.

Immortalized Cells from the Mouse Urogenital Sinus and Adult Mouse Prostate


Wade Bushman

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing mouse cell lines that recapitulate the normal genetic responses of the stromal cells of the urogenital sinus and prostate.
OVERVIEWNo well-characterized prostate stromal cell lines currently exist.
THE INVENTIONA UW-Madison researcher has developed biological material that includes immortalized murine mesenchymal cells from the urogenital sinus and stromal cells from the lobes of the adult prostate. The cells were isolated from the INK4A transgenic mouse, which lacks genes that normally enforce senescence. A construct that expresses lacZ was included in these cells to allow their identification when they are grafted into mouse tissues.
  • A system for screening drugs to treat prostate cancer
  • Novel targets for the design of drugs to treat prostate cancer
  • Useful to examine the role of specific mesenchymal and stromal genes in regulation of prostate growth
  • May enable the identification of specific genes activated in response to prostate tumor cell signals
STAGE OF DEVELOPMENTThe researcher has shown that these cell lines recapitulate the normal genetic responses of the stromal cells of the urogenital sinus and prostate.
For More Information About the Inventors
Contact Information
For current licensing status, please contact Mark Staudt at or 608-960-9845.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.